HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Abortion Pill’s Safety Called into Question in Congressional Actions Based on Misleading Data — The Monitor

False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safety. And competing interpretations of what censorship and free speech mean are impacting how health m

By KFF Health News · Apr 9, 2026 · via KFF Health News
Abortion Pill’s Safety Called into Question in Congressional Actions Based on Misleading Data — The Monitor

Image: KFF Health News

This is an aggregated industry headline. Read the full story at KFF Health News

Tags
policyformat:headlineheadlineKFF Health News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
PolicyFierceBiotech ↗
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-know…
May 25, 2026
Lilly Targets Church-Linked Pharmacies in $200M Trulicity Rebate Fraud Allegation
PolicyBriefing
Eli Lilly’s lawsuit claims church-affiliated pharmacies and wholesalers defrauded it through fake rebate claim…
May 25, 2026
STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further
PolicySTAT News ↗
The Trump administration disclosed plans to reduce state directed payments even more, setting up a probable sh…
May 22, 2026